Skip to content

The Effect of a Plant-based, Protein-dense Sauce on Essential Amino Acid Concentrations and Gut Fullness in Older Adults

Testing the Effect of a Plant-based, Protein-dense Sauce (ProSauce) on Metabolic Availability of Essential Amino Acids and Gut Fullness and Satiety in Older Adults

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06965699
Acronym
ProSauce
Enrollment
20
Registered
2025-05-11
Start date
2025-07-10
Completion date
2026-04-30
Last updated
2025-09-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malnutrition Elderly, Protein Malnutrition

Keywords

plant-based protein sauce, older adults, amino acid metabolic availability, appetite regulation

Brief summary

The goal of this clinical trial is to determine whether meals fortified with plant-based high protein sauce (ProSauce) provide better metabolic availability of essential amino acids compared to meals with standard lower-protein sauce without resulting in excessive gut fullness and satiety. The main questions it aims to answer are: Does meals with high-protein sauce deliver better metabolic availability of amino acid profile? Does this high-protein sauce also not lead to excessive appetite suppression due to its liquid form? Researchers will compare high protein sauce to a commercially available standard low protein sauce. Participants will consume two meals, either protein-fortified or standard low-protein sauce, in a randomised order with at least a one-week washout period between each meal. The investigators will collect venous blood samples over a 6-hour postprandial period to measure plasma essential (and non-essential) amino acid and insulin concentrations. The investigators will also measure appetite-related hormones from venous plasma and assess subjective appetite using a visual analogue scale, taken in parallel with the blood sample time points.

Interventions

DIETARY_SUPPLEMENTProSauce

10g additional protein from ProSauce

DIETARY_SUPPLEMENTlow-protein sauce

Commercially available standard low-protein sauce

Sponsors

University of Exeter
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
60 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Aged 60 and over * Living independently in the community * Capacity to provide informed consent * Non-smoking (vaping is considered smoking) * No known medical conditions that might influence the study outcomes, e.g., heart disease, diabetes mellitus, obesity, disthyroidism and other endocrinopathies and renal failure * Not taking any medications that might influence the study outcomes e.g., taking anabolic steroids or corticosteroids long term * No clinically diagnosed eating disorders * No severe dislike or allergy to any of the study food * No hospitalisations in the last 6 months * Not dieting and weight stable for 3 months before the study (\< 3 kg change in weight)

Exclusion criteria

* Age \< 60y * Smoking * Food allergies * Cognitive and mobility issues * Hospitalisation in the last 6 months * Known medical conditions that might influence the study outcomes * Taking medications that influence the study outcomes

Design outcomes

Primary

MeasureTime frameDescription
Concentrations of essential amino acidsEssential amino acid concentrations at time points of baseline, immediately after breakfast (t =0 minute) and t = 20, 40, 60, 90, 120, 180, 240, 300, 360 minutes.Baseline and postprandial plasma amino acid concentrations will be measured to provides valuable insights into protein digestion and absorption.

Secondary

MeasureTime frameDescription
Concentrations of appetite-related gut hormonesAppetite-related gut hormones will be measured at time points of baseline, immediately after breakfast (t =0 minute) and t = 20, 40, 60, 90, 120, 150, 180, 210, 240 minutes.Plasma appetite-related hormones i.e., acylated ghrelin, PYY, GLP-1, CCK, will be measured at certain time points via cannulation.

Countries

United Kingdom

Contacts

Primary ContactZhuoxiu Jin, Dr
z.jin3@exeter.ac.uk+447529283410
Backup ContactJoanna Bowtell, Prof

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026